Acute Ischemic Stroke (AIS) Therapeutics – Pipeline Assessment and Market Forecasts to 2018

Printer-friendly versionPDF version

The Acute Ischemic Stroke Therapeutics Market is Forecast to Show High Growth until 2018.The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders

GlobalData estimates that the global acute ischemic stroke therapeutics market was valued at $256.5m in 2010, and it is expected to grow at a Compound Annual Growth Rate (CAGR) of 16.7% over the next
eight years, to reach approximately $880m by 2018. This high growth is primarily attributed to the expected launch of three drugs; desmoteplase, a plasminogen activator which can be administered to a
stroke patient within three to nine hours of the stroke onset; RG3626 (an extended timeframe formulation of alteplase), which can be administered within up to 4.5 hours of the onset of stroke; and DP-b99, which is a novel molecule also targeting an extended timeframe of administration. These drugs have a higher therapeutic timeframe and can be given to a stroke patient even after three hours of the onset of stroke, unlike the current formulation of Activase (alteplase). As a result, there would be a higher uptake of these drugs, and more patients can be brought under the treatment umbrella of fibrinolytics, thereby leading to a growth in the market. These drugs, after approval, are expected to be placed at a premium price, which will lead to an increased annual cost of treatment. Thus, the approval of these drugs and the high price associated with them will be the main drivers of the acute ischemic stroke therapeutics market. The current competitive landscape consists of branded as well as generic drugs.
 
The acute ischemic stroke therapeutics market has only two approved drugs in the US and Europe, Activase and Plavix (clopidogrel), of which Activase is for the primary treatment and Plavix is a maintenance therapy, along with other generic anti-platelets such as aspirin. Other anti-coagulants such
as heparin and warfarin are also used to a limited extent as maintenance therapy for the acute phase
treatment of acute ischemic stroke. Additionally, Radicut (edaravone) is approved for the treatment of
ischemic stroke only in Japan, and its Phase II trials are being conducted in Europe. Activase treats the
acute phase of ischemic stroke and thus occupies a major market share for the acute phase. However,
generics also play a considerable role in capturing the market share, as the majority of the patient pool is unable to receive the primary fibrinolytics treatment. This indicates that the competitive landscape for the treatment of acute ischemic stroke (acute phase as well as maintenance therapy) is weak. Physician
satisfaction in terms of Activase treatment is high; however, it can be given to the patient only within three hours of the onset of the stroke, which leaves a significant unmet need for therapies with an extended timeframe of administration. New entrants with better efficacy and safety profiles as well as extended timeframes of administration will offer tough competition to the currently marketed products.
 
For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Acute-Ischemic-Stroke-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2018&Title=Pharmaceuticals_and_Healthca&ReportType=Industry_Report&CompanyID=prpoi
 
The companies with novel molecules in various stages of development will have a major impact on the
future acute ischemic stroke market. D-Pharm Ltd. and H Lundbeck A/S are going to be the key players in the acute ischemic stroke therapeutics market. Additionally, Aldagen, Inc., Celgene Corporation, Corrimum Gmbh, Mitsubhishi Tanabe Pharma, Panacea Pharmaceuticals, Pfizer, Inc., Sanofi, Stemedica
Cell Technologies and Vernalis PLC also have pipeline drugs in the early stages of development. GlobalData has profiles of all these companies, as they hold important drugs in the pipeline for acute ischemic stroke.
 
GlobalData, the industry analysis specialist, has released its new report, “Acute Ischemic Stroke (AIS)Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global acute ischemic stroke therapeutics market. The report
identifies the key trends shaping and driving the global acute ischemic stroke therapeutics market. The
report also provides insights on the prevalent competitive landscape and the emerging players expected
to significantly alter the market positioning of the current market leaders. Most importantly, the report
provides valuable insights on the pipeline products within the global acute ischemic stroke therapeutics
sector. This report is built using data and information sourced from proprietary databases, primary and
secondary research and in-house analysis by GlobalData’s team of industry experts.
 
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Acute-Ischemic-Stroke-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2018&Title=Pharmaceuticals_and_Healthca&ReportType=Industry_Report&CompanyID=prpoi

Visit our report store: http://www.globaldata.com/reportstore
 
For more details contact:
pressreleases@globaldata.com
            
North America:                 +1 646 395 5477
Europe:                                +44 207 753 4299
                                                +44 1204 543 533
Asia Pacific:                         +91 40 6616 6782